The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | Pre-symptomatic diagnosis of AL amyloidosis with biomarker-based screening in patients with MGUS
Silvia Mangiacavalli, MD, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy, shares the results of a study investigating the possibility of diagnosing pre-symptomatic AL amyloidosis in patients with monoclonal gammopathy of undetermined significance (MGUS) using a biomarker-based screening program. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
